The most modern technology to carry out each technique with the maximum guarantee of success
The Instituto Valenciano de Infertalidad (IVI), founded in 1990, is the first medical institution in Spain that is completely specialized in reproductive medicine. In its seventeen years of existence, it has been instrumental in the births of more than 20,000 children.
This clinic is at the forefront of reproductive medicine and its philosophy is based on maximum personal attention, providing concrete solutions specifically for each person. The method starts with research into the couple and involves analysis, diagnosis, development of the treatment and its application, up to evaluation of the results, all combined with continuous monitoring that throws light on other therapeutic options, in case it is necessary to change the treatment or repeat it in another cycle. All this coupled with the most modern technology to carry out each technique with the maximum guarantee of success.
Ever since its start, IVI has shown steady growth and is currently one of the largest of its type in Europe. Currently the company consists of thirteen centres (IVI Almería, IVI Barcelona, IVI Castellón, IVI Madrid, IVI Murcia, and IVI Sevilla, IVI Valencia and IVI Vigo; and outside Spain, IVI México, IVI Lisboa and IVI Santiago de Chile). Several more are scheduled for opening in the near future.
The first of these openings will be in Valencia, the city where the company was founded. As the range of treatment that is performed by IVI is increasing steadily, there is a need for a second centre, which will open in January 2008 to allow providing the best services. Next to the growing number of treatments and the growing need for laboratory space that accompanies this, IVI also invests heavily in R&D. This year they have budgeted 2.5 million euros to this purpose, one of the biggest budgets of this type.
The MCO Multigas Incubator MCO-5M optimally fitted their needs
IVI Valencia has been testing the MCO Multigas Incubator MCO-5M during 2007 and reached the conclusion that these space-saving personal type multigas incubators optimally fitted their needs. The first tests covered unit performance of the unit when used at a lowered oxygen level followed by tests on embryos. Both testing sequences achieved excellent results with IVI deciding to purchase 24 units.
The human reproduction industry is growing all over the world. PHC is strongly focused on this market with several new products to be introduced shortly. The cooperation between PHC and IVI is sure to have benefits for applications in human reproduction.
The contents above based on the information before April 2018.
On April 1st, 2018, Panasonic Healthcare Co., Ltd. changed the company name to PHC Corporation and our biomedical products are sold under the business brand name PHCbi.